CMOPF
Price
$55.00
Change
-$7.80 (-12.42%)
Updated
Apr 10 closing price
Capitalization
827.91M
GSK
Price
$38.06
Change
+$0.63 (+1.68%)
Updated
Apr 28 closing price
Capitalization
88.13B
One day until earnings call
Ad is loading...

CMOPF vs GSK

Header iconCMOPF vs GSK Comparison
Open Charts CMOPF vs GSKBanner chart's image
Cosmo Pharmaceuticals
Price$55.00
Change-$7.80 (-12.42%)
Volume$200
Capitalization827.91M
GSK
Price$38.06
Change+$0.63 (+1.68%)
Volume$5.76M
Capitalization88.13B
CMOPF vs GSK Comparison Chart
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMOPF vs. GSK commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMOPF is a Hold and GSK is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (CMOPF: $55.00 vs. GSK: $38.06)
Brand notoriety: CMOPF and GSK are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: CMOPF: 57% vs. GSK: 101%
Market capitalization -- CMOPF: $827.91M vs. GSK: $88.13B
CMOPF [@Pharmaceuticals: Major] is valued at $827.91M. GSK’s [@Pharmaceuticals: Major] market capitalization is $88.13B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMOPF’s FA Score shows that 1 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • CMOPF’s FA Score: 1 green, 4 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, GSK is a better buy in the long-term than CMOPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 7 TA indicator(s) are bullish.

  • GSK’s TA Score: 7 bullish, 4 bearish.

Price Growth

CMOPF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while GSK (@Pharmaceuticals: Major) price change was +4.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.83%. For the same industry, the average monthly price growth was -1.25%, and the average quarterly price growth was -8.10%.

Reported Earning Dates

GSK is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+4.83% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GSK($88.1B) has a higher market cap than CMOPF($828M). CMOPF has higher P/E ratio than GSK: CMOPF (68.49) vs GSK (14.01). GSK YTD gains are higher at: 13.770 vs. CMOPF (-17.819). GSK has higher annual earnings (EBITDA): 9.08B vs. CMOPF (42.1M). GSK has more cash in the bank: 4.99B vs. CMOPF (222M). CMOPF has less debt than GSK: CMOPF (176M) vs GSK (18B). GSK has higher revenues than CMOPF: GSK (30.3B) vs CMOPF (104M).
CMOPFGSKCMOPF / GSK
Capitalization828M88.1B1%
EBITDA42.1M9.08B0%
Gain YTD-17.81913.770-129%
P/E Ratio68.4914.01489%
Revenue104M30.3B0%
Total Cash222M4.99B4%
Total Debt176M18B1%
FUNDAMENTALS RATINGS
CMOPF vs GSK: Fundamental Ratings
CMOPF
GSK
OUTLOOK RATING
1..100
5027
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
9
Undervalued
PROFIT vs RISK RATING
1..100
10058
SMR RATING
1..100
5647
PRICE GROWTH RATING
1..100
8651
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for CMOPF (50) in the null industry. This means that GSK’s stock grew somewhat faster than CMOPF’s over the last 12 months.

GSK's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for CMOPF (100) in the null industry. This means that GSK’s stock grew somewhat faster than CMOPF’s over the last 12 months.

GSK's SMR Rating (47) in the Pharmaceuticals Major industry is in the same range as CMOPF (56) in the null industry. This means that GSK’s stock grew similarly to CMOPF’s over the last 12 months.

GSK's Price Growth Rating (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for CMOPF (86) in the null industry. This means that GSK’s stock grew somewhat faster than CMOPF’s over the last 12 months.

GSK's P/E Growth Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for CMOPF (100) in the null industry. This means that GSK’s stock grew significantly faster than CMOPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSK
RSI
ODDS (%)
Bullish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
43%
Momentum
ODDS (%)
Bullish Trend 1 day ago
56%
MACD
ODDS (%)
Bullish Trend 1 day ago
53%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
56%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
50%
Advances
ODDS (%)
Bullish Trend 5 days ago
54%
Declines
ODDS (%)
Bearish Trend 21 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
67%
Aroon
ODDS (%)
Bearish Trend 1 day ago
41%
View a ticker or compare two or three
Ad is loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAYEX20.000.06
+0.30%
Oakmark International Small Cap Advisor
SVPIX92.50N/A
N/A
ProFunds Small Cap Value Inv
CFIPX23.97N/A
N/A
Franklin Global Equity A
NAIGX30.79N/A
N/A
Nuveen International Value A
POGRX32.61N/A
N/A
PRIMECAP Odyssey Growth

CMOPF and

Correlation & Price change

A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMOPF
1D Price
Change %
CMOPF100%
N/A
GSK - CMOPF
22%
Poorly correlated
+1.68%
NVS - CMOPF
21%
Poorly correlated
+0.44%
CHGCY - CMOPF
7%
Poorly correlated
-2.36%
DSNKY - CMOPF
5%
Poorly correlated
+0.14%
CSPCY - CMOPF
4%
Poorly correlated
-1.28%
More